Avalo Therapeutics (AVTX) vs Helus Pharma (HELP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Helus Pharma (HELP) has outperformed Avalo Therapeutics (AVTX) over the past year, gaining 71.2% versus a loss of 5.6%. Over five years, HELP leads with a -85.7% price change compared with -99.8% for AVTX. Helus Pharma is the larger company by market cap ($783.2 million vs $720.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVTX | HELP |
|---|---|---|
| Share price | $13.43 | $10.72 |
| Market cap | $720.25M | $783.21M |
| 1-day change | -1.10% | +2.00% |
| YTD return | -26.05% | +31.05% |
| 1-year return | -5.56% | +71.25% |
| 5-year return | -99.79% | -85.68% |
| EPS (TTM) | $-4.26 | $-4.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $24.27 | $15.15 |
| 52-week low | $12.51 | $3.76 |
| Distance from 52-week high | -44.66% | -29.24% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +228.22% | +271.55% |
| Average volume | 925.93K | 1.77M |
| Shares outstanding | 53.63M | 73.06M |
| Employees | 33 | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HELP has outperformed AVTX by 76.8 percentage points over the past year.
About Avalo Therapeutics
AVTX stock →Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees
About Helus Pharma
HELP stock →Helus Pharma Inc., doing business as Helus Pharma, operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder; and HLP004, a deuterated N, N-dimethyltryptamine, which is in phase 2 clinical trial for treating generalized anxiety disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
AVTX vs HELP FAQ
Which is bigger, Avalo Therapeutics or Helus Pharma?
Helus Pharma (HELP) is larger, with a market capitalization of $783.21M compared with $720.25M for Avalo Therapeutics (AVTX).
Which stock has performed better over the past year, AVTX or HELP?
HELP returned +71.25% over the past 12 months, compared with -5.56% for AVTX (price return, excluding dividends). Past performance does not predict future results.
Are Avalo Therapeutics and Helus Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.